Natural sources as potential anti-cancer agents: A review

International Journal of Phytomedicine

Volumn 3, Issue 1, 2011, Pages 09-26

  Bhanot, Abhishek ^a   Sharma, Rohini ^a   Noolvi, Malleshappa N ^a  

^a Amar Shaheed Baba Ajit Singh Jujhar Singh Memorial College of Pharmacy   (India)

Author keywords

Cancer; Fruit; Vegetables; Vinblastin; Vincristin

Indexed keywords

ANTINEOPLASTIC AGENT; BRYOSTATIN 1; DEHYDRODIDEMNIN B; DIDEMNIN B; DOCETAXEL; DOLASTATIN 10; ETOPOSIDE; HERBACEOUS AGENT; IRINOTECAN; NATURAL PRODUCT; PACLITAXEL; TOPOTECAN; TRABECTEDIN; VINBLASTINE; VINCRISTINE;

ANTINEOPLASTIC ACTIVITY; BLADDER CANCER; BREAST CANCER; CANCER PREVENTION; CELL CYCLE ARREST; CELL CYCLE G1 PHASE; CHILDHOOD CANCER; COLORECTAL CANCER; DRUG MECHANISM; DRUG SCREENING; GERM CELL TUMOR; HEAD AND NECK CANCER; HUMAN; KIDNEY CANCER; LEUKEMIA; LUNG CANCER; LUNG SMALL CELL CANCER; LYMPHATIC LEUKEMIA; LYMPHOMA; MARINE SPECIES; MEDICINAL PLANT; MELANOMA; MICROORGANISM; NONHODGKIN LYMPHOMA; NONHUMAN; OVARY CANCER; REVIEW; SOLID TUMOR;

EID: 79960323899     PISSN: None     EISSN: 09750185     Source Type: Journal    
DOI: None     Document Type: Review

References (185)

1. Hail Jr N. Mitochondria: a novel target for the chemoprevention of cancer. Apoptosis. 2005;10:687-705.
2. Aggarwal BB, Danda D, Gupta S, Gehlot P. Models for prevention and treatment of cancer: Problems vs promises. Biochem Pharmacol. 2009;78:1083-1094.
3. Farnsworth NR. Ethnobotany and the Search for New Drugs, Wiley Willett WC. Diet and health: what should we eat. Science. 1994;264(5158):532-7.
4. Duraipandiyan V, Ayyanar M, Ignacimuthu S. Antimicrobial activity of some ethnomedicinal plants used by Paliyar tribe from Tamil Nadu, India. BMC Comp Alter Med. 2006;6:35-41.
5. Cragg GM, Kingston DGI, Newman DJ. Anticancer Agents from Natural Products. Taylor & Francis Group, Boca Raton, FL. Brunner-Routledge Psychology Press; 2005.
6. Cragg GM, Newman D J, Weiss RB. Coral reefs, forests, and thermal vents: the worldwide exploration of nature for novel antitumor agents. Semin Oncol. 1997;24:156-163.
7. Newman DJ, Cragg GM. Natural products as sources of new drugs over the last 25 years. J Nat Prod. 2007;70:461-477.
8. Butler MS. Natural products to drugs: natural product derived compounds in clinical trials. Nat Prod Rep. 2005;22:162-195.
9. Bailly C. Ready for a comeback of natural products in oncology. Biochem Pharmacol. 2009;77:1447-1457.
10. Newman DJ, Cragg GM, Snader KM. Natural products as sources of new drugs over the period 1981-2002. J Nat Prod. 2003;66: 1022-1037.
11. Butler MS. The role of natural product chemistry in drug discovery. J Nat Prod. 2004;67:2141-2153.
12. DeVita VT Jr, Serpick AA, Carbone PO. Combination chemotherapy in the treatment of advanced Hodgkin's disease. Ann Intern Med. 1970;73:881-895.
13. Noble RL. The discovery of the vinca alkaloids-chemotherapeutic agents against cancer. Biochem Cell Biol. 1990;68:1344-1351.
14. Stähelin H. Actvity of a new glycosidic lignan derivative (VP-16-213) related to podophyllotoxin in experimental tumors. Eur J Cancer. 1973;9:215-221.
15. Harvey AL. Medicines from nature: are natural products still relevant to drug discovery. Trends Pharmacol Sci. 1999;20:196-198.
16. Liu LF. DNA topoisomerase poisons as antitumor drugs. Annu Rev Biochem. 1989;58:351-375.
17. Wani MC, Taylor HL, Wall ME, et al. Plant antitumor agents. VI. The isolation and structure of taxol, a novel antileukemic and antitumor agent from Taxus brevifolia. J Am Chem Soc. 1971;93:2325-2327.
18. Creemers GJ, Bolis G, Gore M, et al. Topotecan, an active drug in the second-line treatment of epithelial ovarian cancer. J Clin Oncol. 1996;14:3056-3061.
19. Bertino JR. Irinotecan for colorectal cancer. Semin Oncol. 1997;24:S18-S23.
20. Liu LF, Desai SD, Li TK, et al. Mechanism of action of camptothecin. Ann New York Acad Sci. 2000;922:1-10.
21. Harmon AD, Weiss U, Silverton JV. The structure of rohutukine, the main alkaloid of Amoora rohituka (syn. Aphanamixis polystachya) (Maliaceae). Tetrahydron. 1979;20:721-724.
22. Cragg G, Suffness M. Metabolism of plant-derived anticancer agents. Pharmacol Ther. 1988;37:425-432.
23. Losiewicz MD, Carlson BA, Kaur G, et al. Potent inhibition of cdc2 kinase activity by the flavonoid L86-8275. Biochem Biophys Res Commun. 1994;201:589-595.
24. Worland PJ, Kaur G, Stetler-Stevenson M, et al. Alteration of the phosphorylation state of p32cdc2 kinase by the flavone L86-8275 in breast carcinoma cells. Biochem Pharmacol. 1993;46:1831-1836.
25. Kelland LR. Flavopiridol, the first cyclin-dependent kinase inhibitor to enter the clinic: current status. Ex Opin Inv Drugs. 2000;9:2903-2911.
26. Powell RG, Weisleder D, Smith CR Jr, et al. Structures of harringtonine, isoharringtonine, and homoharringtonine. Tetrahydron Lett. 1970;11:815-818.
27. Zhou DC, Zittoun R, Marie JP. Homoharringtonine: an effective new natural product in cancer chemotherapy. Bull Cancer. 1995;82:987-995.
28. Kantarjian HM, O'Brien S, Anderlini P, et al. Treatment of myelogenous leukemia: current status and investigational options. Blood. 1996;87:3069-3081.
29. Rowinsky EK, Noe DA, Ettinger DS, et al. PhaseI and pharmacological study of the pulmonary cytotoxin 4-ipomeanol on a single dose schedule in lung cancer patients: hepatotoxicity is dose limiting in humans. Cancer Res. 1993;53:1794-1801.
30. Rehm S, Devor DE. Acute effects of 4-ipomeanol on experimental lung tumors with bronchiolar or alveolar cell features in Syrian hamsters or C3H/HeNCr mice. J Cancer Res Clin Oncol. 1993;120:41-50.
31. Li YZ, Li CJ, Pinto AV, et al. Release of mitochondrial cytochrome c in both apoptosis and necrosis induced by β-lapachone in human carcinoma cells. Mol Med. 1999;4:232-239.
32. Vukovic-Gacic B, Nikcevic S, Beric-Bjedov T, et al. Antimutagenic effect of essential oil of sage (Salvia officinalis L.) and its monoterpenes against UV-induced mutations in Escherichia coli and Saccharomyces cerevisiae. Food Chem Toxicol. 2006;44:1730-1738.
33. ÖnayUçar E, Karagöz A, Arda N. Antioxidant activity of Viscum album sp. Fitoterapia. 2006;77: 556-560.
34. Pinney KG, Jelinek C, Edvardsen K, et al. The discovery and development of the combretastatins. In: Cragg GM, Kingston DGI, Newman DJ. Anticancer Agents from Natural Products. Taylor & Francis Group, Boca Raton, FL Brunner-Routledge Psychology Press; 2005:23-46 (Chapter 3).
35. Evandri MG, Battinelli L, Daniele C, et al. The antimutagenic activity of Lavandula angustifolia (lavender) essential oil in the bacterial reverse mutation assay. Food Chem Toxicol. 2005;43:1381-1387.
36. Hwang BY, Su BN, Chai H, et al. Silvestrol and episilvestrol, potential anticancer rocaglate derivatives from Aglaia silvestris. J Org Chem. 2004;69(10):3350-3358.
37. Cassady JM, Chan KK, Floss HG, et al. Recent developments in the Maytansanoid antitumor agents. Chem Pharma Bulletin. 2004;52:1-26.
38. Suffness M, Douros J. Miscellaneous natural products with antitumor activity. In: Cassady JM, Douros JD. Anticancer Agents Based on Natural Product Models. New York, Academic Press; 1980:474 (Chapter 14).
39. Ravelo AG, Estevez-Braun A, Chavez-Orellana H, et al. Recent studies on natural products as anticancer agents. Curr Topics Med Chem. 2004;4:241-265.
40. Jang DS, Park EJ, Hawthorne ME, et al. Potential cancer chemopreventive constituents of the seeds of Dipteryx odorata (tonka bean). J Nat Prod. 2003;66(5):583-587.
41. Denmeade SR, Jakobsen CM, Janssen S, et al. Prostate-specific antigen-activated thapsigargin prodrug as targeted therapy for prostate cancer. J Natl Cancer Inst. 2003;95:990-1000.
42. Newman DJ, Cragg GM, Holbeck S, et al. Natural products as leads to cell cycle pathway targets in cancer chemotherapy. Curr Cancer Drug Targets. 2002;2:279-308.
43. Hernandez-Ceruelos A, Madrigal-Bujaidar E, de la Cruz C. Inhibitory effect of chamomile essential oil on the sister chromatid exchanges induced by daunorubicin and methyl methanesulfonate in mouse bone marrow. Toxicol Lett. 2002;135:103-110.
44. Silva GL, Cui B, Chavez D, et al. Modulation of the multidrug-resistance phenotype by new tropane alkaloid aromatic esters from Erythroxylum pervillei. J Nat Prod. 2001;64(12):1514-1520.
45. Lee D, Bhat KPL, Fong HHS, et al. Aromatase inhibitors from Broussonetia papyrifera. J Nat Prod. 2001;64(10):1286-1293.
46. Marnewick JL, Gelderblom WCA, Joubert E. An investigation on the antimutagenic properties of South African herbal teas. Mutat Res. 2000;471:157-166.
47. Abdulla M, Gruber P. Role of diet modification in cancer prevention. Biofactors. 2000;12:45-51.
48. Dinkova-Kostova AT, Talalay P. Persuasive evidence that quinine reductase type 1 (DT diaphorase) protects cells against the toxicity of electrophiles and reactive forms of oxygen. Free Radic Biol Med. 2000;29(3-4): 231-240.
49. Sausville EA, Zaharevitz D, Gussio Z, et al. Cyclin-dependent kinases: initial approaches to exploit a novel therapeutic target. Pharmacol Thera. 1999;82:285.
50. He K, Valcic S, Timmerman BN, et al. Indole alkaloids from Aristotelia chilensis (Mol.) Stuntz. Int J Pharmacog. 1997;35:215-217.
51. Khamis SB, Brown JE, Bibby MC, et al. Evaluation of two plants species used in Malay traditional medicine for the treatment of breast cancer. J Pharma Pharmacol. 1997;49:113.
52. Liang HR, Vuorela P, Vuorela H, et al. Isolation and immunomodulatory effect of flavonol glycosides from Epimedium hunanense. Planta Medica. 1997;63:316-319.
53. Peres MTLP, Monache FD, Cruz AB, et al. Chemical composition and antimicrobial activity of Croton urucurana Baillon (Euphorbiaceae). J Ethnopharmacol. 1997;56:223-226.
54. Barakat HH, Hussein SAM, Marzour MS, et al. Polyphenolic metabolites of Epilobium hersutum. Phytochemistry. 1997;46:935-941.
55. Bai L, Yamaki M, Takagi S. Lignans and a bichroman from Pleione bulbocodioides. Phytochemistry. 1997;44:341-343.
56. Jang M, Cai L, Udeani GO, et al. Cancer chemopreventive activity of resveratrol, a natural product derived from grapes. Science. 1997;275(5297):218-220.
57. Gupta MP, Monge A, Karikas GA, et al. Screening of Panamanian medicinal plants for brine shrimp toxicity, crown gall tumor inhibition, cytotoxicity and DNA intercalation. Int J Pharmacog. 1996;34:19-27.
58. Suh HW, Song DK, Son KH, et al. Antinociceptive effect of Smilaxin B administered intracerebroventricularly in the mouse. Planta Med. 1996;62:141-145.
59. Shirota O, Tamemura T, Morita H, et al. Triterpenes from Brazilian medicinal plant "Chuchuhuasi" (Maytenus krukobii). J Nat Prod. 1996;59:1072-1075.
60. Tsui WY, Brown GD. Cycloeudesmanolides from Sarcandra glabra. Phytochemistry. 1996;43:819-821.
61. Um SH, Lee KR, Zee OP, Pyo S. The effect of Salvia plebeia on murine macrophage-mediated cytotoxicity. Nat Prod Sci. 1996;2: 43-47.
62. Ducki S, Hadfield JA, Lawrence CY, et al. Isolation of E-1-(4'-hydroxyphenyl)-But-1-en-3-one from Scutellaria barbata. Planta Med. 1996;62:185-186.
63. Palomino E, Maldonado C, Kempff MB, et al. Caparratriene, an active sesquiterpene hydrocarbon from Ocotea caparrapi. J Nat Prod. 1996;59:77-79.
64. Singh VK, Ali ZA, Zaidi STH, et al. Ethnomedicinal uses of plants of Gonda district forests of Uttar Pradesh, India. Fitoterapia. 1996;67:129-139.
65. Flores JS, Ricalde RV. The secretions and exudates of plants used in mayan traditional medicine. J Herbs Spices Med Plants. 1996;4:53-59.
66. Ahn BT, Oh KJ, Ro JS, Lee KS. A new flavonoid from Euphorbia ebracteolata. Planta Med. 1996;62:383-384.
67. Hu K, Dong A, Yao XS, et al. Antineoplastic agents I. Three spirostanol glycosides from rhizomes of Dioscorea collettii var. hypoglauca. Planta Med. 1996;62:573-575.
68. Joe YK., Son JK, Park SH, et al. New naphthalenyl glucosides from the roots of Juglans mandshurica. J Nat Prod. 1996;59:159-160.
69. Zeng, JF, Li GL, Zhu DY. Two isoprenoid-subsititued isoflavans from roots of Maackia tenuifolia. Phytochemistry. 1996;43:893-896.
70. Martinez-Lirola MJ, Gonzalez-Tejero MR, Molero-Mesa J. Ethnobotanical resources in the province of Almeria, Spain, Campos De Nijar. Econ Bot. 1996;50:40-56.
71. Peng JN, Feng XZ, Liang XT. A new Iridoid from Hedyotis crysotrichae. Chin Chem Lett. 1995;6:965-966.
72. Ducki S, Hadfield JA, Lawrence NJ, et al. Isolation of paeonol from Arisaema eubescens. Planta Med. 1995;61:586-587.
73. Aquino R, Pizza C, De Tommasi N, et al. New polyoxypregnane ester derivatives from Leptadenia hastata. J Nat Prod. 1995;58:67.
74. Tiwari VJ. Ethnobotanical survey of Halbi tribe of Chandrapur and Gadchiroli districts of Maharashtra State, India. Fitoterapia. 1995;66:346-350.
75. Rabi T, Gupta RC. Antitumor and cytotoxic investigation of Amoora rohituka. Int J Pharmacog. 1995;33:359-361.
76. Ho LK, Ou JC, Sun ML, Sun CM. Two rare alkaloids from Pratia nummularia. Planta Med. 1995;61:567-568.
77. Rivera D, Obon C. The Ethnopharmacology of Madeira and Porto Santo islands, a review. J Ethnopharmacol. 1995;46:73-93.
78. Shirota O, Morita H, Takeya K, Itokawa H. Structures of xuxuarines, stereoisomeric triterpene dimmers from Maytenus chuchuhuasca. Tetrahedron. 1995;51:1107-1120.
79. Fujita T, Sezik E, Tabata M, et al. Traditional medicine in Turkey VII. Folk medicine in middle and west Black sea regions. Econ Bot. 1995;49:406-422.
80. Shi JG, Jia ZJ, Cui YX. Novel Tricyclic Diterpenoids from Euphorbia micractina. J Nat Prod. 1995;58:51-56.
81. Wu DG, Sorg B, Hecker E. New myrsinol-related polyfunctional pentacyclic diterpene esters from roots of Euphorbia prolifera. J Nat Prod. 1995;58:408-413.
82. Gonzalez-Tejero MR, Molero-Mesa J, Casares-Porcel M, et al. New Contributions to the ethnopharmacology of Spain. J Ethnopharmacol. 1995;45:157-163.
83. Ahmad FB, Holdsworth DK. Traditional medicinal plants of Sabah, Malaysia part III. The Rungus people of Kudat. Int J Pharmacog. 1995;33:262-264.
84. Amusan OOG, Msonthi JD, Makhubu LP. Molluscicidal activity of Spathodea campanulata, Andrachneovalis, Phytolacca dodecandra and Hypoxis rooperi. Fitoterapia. 1995;66:113-116.
85. Zani CL, Chaves PPG, Queiroz R, et al. Brine shrimp lethality assay as a prescreening system for anti-trypanosoma cruzi activity. Phytomedicine. 1995;2:47-50.
86. Pisha E, Chai H, Lee IS, et al. Discovery of betulinic acid as a selective inhibitor of human melanoma that functions by induction of apoptosis. Nat Med. 1995;1(10):1046-1051.
87. Laferriere JE. Medicinal plants of the lowland Inga people of Colombia. Int J Pharmacog. 1994;32:90-4.
88. Lin LZ, Hu SF, Zaw K, et al. Thalifaberidine, a cytotoxic aporphine-benzylisoquinoline alkaloid from Thalictrum faberi. J Nat Prod. 1994;57:1430-1436.
89. Bae K H, Min BS, Park KI, Ahn BZ. Cytotoxic flavonoids from Scutellaria indica. Planta Med. 1994;60:280-281.
90. Ishiguro K, Nagata S, Fukumoto H, et al. A 2-pyrone derivative from Hypericum japonicum. Phytochemistry. 1994;37:283-284.
91. Chiang HC, Juilo Y, Lu FJ. Xanthine oxidase inhibitors from the leaves of Alsophila spinulosa (Hook) Tryon. J Enzyme Inhib. 1994;8:61-71.
92. Wu JB, Cheng YD, Kuo SC, et al. Fissoldhimine, a novel skeleton alkaloid from Fissistigma oldhamii. Chem Pharm Bulletin. 1994;42:2202-2204.
93. Pinto DCG, Fuzzati N, Pazmino XC, Hostettmann K. Xanthone and antifungal constituents from Monnina obtusifolia. Phytochemistry. 1994;37:875-878.
94. Liu WK, Ng TG, Sze SF, Tsui KW. Activation of peritoneal macrophages by polysaccharopeptide from the mushroom, Coriolus 6ersicolor. Immunopharmacology. 1993;26:139-146.
95. Mohandoss S, Ravindran P. Flavonoids from Melastoma melabathricum. Fitoterapia. 1993;64:277-278.
96. Hammer M L A, Johns EA. Tapping an Amazonian plethora, four medicinal plants of Marajo Island, Para (Brazil). J Ethnopharmacol. 1993;40:53-75.
97. Segura-Correa R, Mata R, Anaya AL, et al. New tetranortriterpenoids from Swietenia humilis. J Nat Prod. 1993;56:1567-1574.
98. Ghazanfar SA, Al-Sabahi MA. Medicinal plants of Northern and Central Oman (Arabia). Econ Bot. 1993;47:89-98.
99. Cai Y, Chen JP, Phllipson J. Diterpenes from Croton lechleri. Phytochemistry. 1993;32:755-760.
100. Hussain SJ, Alvi AB, Jahan M. A study on Unani medicinal plants, Asteratiqus. J Res Educ Indian Med. 1993;2:35-39.
101. Lin CC, Lin CH. Pharmacological and pathological studies on Taiwan folk medicine. IX. The hepatoprotective effect of the methanolic extract from Echinops grijisii. Am J Chin Med. 1993;21:33-44.
102. Omino EA, Kokwaro JO. Ethnobotany of Apocynaceae species in Kenya. J Ethnopharmacol. 1993;40:167-180.
103. Rehm S, Devor DE. Acute effects of 4-ipomeanol on experimental lung tumors with bronchiolar or alveolar cell features in Syrian hamsters or C3H/HeNCr mice. J. Cancer Res Clin Oncol. 1993;120:41-50.
104. Stuppner H, Sturm S, Geisen G, et al. A differential sensitivity of oxindole alkaloids to normal and leukemic cell lines. Planta Med. 1993;supplement A:583.
105. Holdsworth DK. A preliminary study of medicinal plants of Easter Island, South Pacific. Int J Pharmacog. 1992;30:27-32.
106. Sun HD, Zhou QZ, Fujita T, et al. Rubescensin D, a diterpenoid from Rabdosia rubescens. Phytochemistry. 1992;31:1418-1419.
107. Qian TX, Li LN. Isosalvianolic acid C, a depside possessing a dibenzooxepin skeleton. Phytochemistry. 1992;31:1068-1070.
108. Furusawa E, Chou SC, Furusawa S, et al. Antitumour activity of Ganoderma lucidum, an edible mushroom, on intraperitoneally implanted lewis lung carcinoma in synergenic mice. Phytother Res. 1992;6:300-304.
109. Ding YL, Jia ZA. Two phenolic derivatives from Euphorbia kansui. Phytochemistry. 1992;31:1435-1436.
110. Lin CC, Lin CH, Chiu HF, et al. The Pharmacological and pathological studies on Taiwan folk medicine (VII). The anti-inflammatory effect of Echinops grjiisii. Am J Chin Med. 1992;22:127-134.
111. De Feo V, Aquino R, Menghini A, et al. Traditional phytotherapy in the peninsula Sorrentina, Campania, Southern Italy. J Ethnopharmacol. 1992;36:113-125.
112. Wong BYY, Lau BHS, Teel RW. Chinese medicinal herbs modulated mutagenesis, DNA binding and metabolism of Benzo[A]Pyrene. Phytother Res. 1992;6:10-14.
113. Hua YY. Two new saponins from the roots of Phytolacca esculenta. Planta Med. 1992;58:99-101.
114. Sakagami H, Konno K, Kawazoe Y, et al. Multiple immunological functions of extract from the cone of Japanese white pine, Pinus par6iflora Sieb. et Zucc. Adv Exp Med Biol. 1992;319:331-335.
115. Kao WJ, Hung DZ, Tsai WJ, et al. Podophyllotoxin intoxication. Toxic effect of Bajiaolian in herbal therapeutics. Hum Exp Toxicol. 1992;11:480-487.
116. Lee IR, Song JY, Lee YS. Cytotoxicity of folkloric medicines in murine and human cancer cells. Kor J Pharmacog. 1992;23:132-136.
117. Reddy MB, Reddy KR, Reddy MN. Ethnobotany of Cuddapah district, Andhra Pradesh, India. Int J Pharmacog. 1991;29:273-280.
118. Chhabra SC, Mahunnah RLA, Mshiu MN. Plants used in traditional medicine in Eastern Tanzania. V. Angiosperms (Passifloraceae to Sapindaceae). J Ethnopharmacol. 1991;33:143-157.
119. Holdsworth DK. Traditional medicinal plants of Rarotonga, Cook Islands. Part II. Int J Pharmacog. 1991;29:71-79.
120. Kijjoa A, Gonzalez MJTG, Pinto MMM, et al. Constituents of Knema laurina and Knema tenuiner6ia subsp. setosa. Planta Med. 1991;57:575-577.
121. Sati OP, Bahuguna S, Uniyal S, et al. A new saponin from Deeringia amaranthoides. J Nat Prod. 1990;53:466-469.
122. Konda Y, Iguchi M, Harigaya Y, et al. Hancokinol, a novel triterpene, from Cynanchum hancokianum. Tetrahedron Lett. 1990;31:5315-5318.
123. Bhat RB, Eterjere EO, Oladipo VT. Ethnobotanical studies from Central Nigeria. Econ Bot. 1990;44:382-390.
124. Plotkin MJ, Schultes RE. Virola, a promising genus for ethnopharmacological investigation. J Psychoactive Drugs. 1990;22:357-361.
125. Novaretti R, Lemordant D. Plants in the traditional medicine of the Ubaye valley. J Ethnopharmacol. 1990;30:1-34.
126. Uniyal MR. Utility of hitherto unknown medicinal plants traditionally used in Ladakh. J Res Educ Indian Med. 1990;9:89-95.
127. Vinesi P, Serafini M, Nicoletti M, et al. Plant regeneration and hypoxoside content in Hypoxis obtusa. J Nat Prod. 1990;53:196-199.
128. Chu DT, Wong WL, Mavlight GM. Immunotherapy with Chinese medicinal herbs: immune restoration of local xenogenic graft-versus-host reaction in cancer patients by fractionated Astragalus membranacueus in vitro. J Clin Lab Immunol. 1988;25(3):19-23.
129. Kokwaro JO. Medicinal plants of east Africa. East African Literature Bureau, Nairobi;1976.
130. Powell RG, Weisleder D, Smith CR Jr, et al. Structures of harringtonine, isoharringtonine, and homoharringtonine. Tetrahydron Lett. 1970;11: 815-818.
131. Block G, Patterson B, Subar A. Fruit, vegetables, and cancer prevention: a review of the epidemiological evidence. Nutr Cancer. 1992;18(1):1-29.
132. Steinmetz KA, Potter JD. Vegetables, fruit, and cancer prevention: a review. J Am Diet Assoc. 1996;96(10):1027-39.
133. Reddy L, Odhav B, Bhoola KD. Natural products for cancer prevention: a global perspective. Pharmacol Ther. 2003;99(1):1-13.
134. Aggarwal BB, Shishodia S. Molecular targets of dietary agents for prevention and therapy of cancer. Biochem Pharmacol. 2006;71:1397-1421.
135. Hoyoku N, Michiaki M, Harukuni T, et al. Cancer prevention by carotenoids. Arch Biochem Biophys. 2009;483:(2):165-168.
136. Wan X, Luo M, Li X, et al. Hepatoprotective and anti-hepatocarcinogenic effects of glycyrrhizin and matrine. Chem Biol Interact. 2009;181:(1)15-19.
137. Caihua L, Michael DMc, Carmen M, et al. A Population-Based Case-Control Study of Marijuana Use and Head and Neck Squamous Cell Carcinoma. Cancer Prev Res. 2009;2(8):759-768.
138. Shiu-Chen H, Chi-Tang H, Shoei-Yn L, et al. Carnosol inhibits the invasion of B16/F10 mouse melanoma cells by suppressing metalloproteinase-9 through down-regulating nuclear factor-kappa B and c-Jun. Biochem Pharmacol. 2005;69(2):221-232.
139. Li M, Zhang Z, Hill DL, et al. Genistein, a dietary isoflavone, down-regulates the MDM2 oncogene at both transcriptional and posttranslational levels. Cancer Res. 2005;65(18):8200-8.
140. Ruiz D, Egea J, Tomas-Barberan FA, et al. Carotenoids from new apricot (Prunus armeniaca L.) varieties and their relationship with flesh and skin color. J Agric Food Chem. 2005;53:6368-74.
141. Kim GY, Kim JH, Ahn SC, et al. Lycopene suppresses the lipopolysaccharide-induced phenotypic and functional maturation of murine dendritic cells through inhibition of mitogen-activated protein kinases and nuclear factor-kappaB. Immunology. 2004;113(2):203-11.
142. Sunila ES, Kuttan G. Immunomodulatory and antitumor activity of Piper longum Linn. and piperine. J Ethnopharmacol. 2004;90:(2-3):339-346.
143. Shishodia S, Majumdar S, Banerjee S, et al. Ursolic acid inhibits nuclear factor-kappaB activation induced by carcinogenic agents through suppression of IkappaBalpha kinase and p65 phosphorylation: correlation with down regulation of cyclooxygenase 2, matrix metalloproteinase 9, and cyclin D1. Cancer Res. 2003;63(15):4375-83.
144. Takada Y, Aggarwal BB. Betulinic acid suppresses carcinogen-induced NF-kappa B activation through inhibition of I kappa B alpha kinase and p65 phosphorylation: abrogation of cyclooxygenase-2 and matrix metalloprotease-9. J Immunol. 2003;171(6):3278-86.
145. Cheng YH., Shen TF, Pang VF, et al. Effects of aflatoxin and carotenoids on growth performance and immune response in mule ducklings. Comp Biochem Physiol Toxicol Pharmacol. 1999;128:19-26.
146. Abdullaev FI. Cancer chemopreventive and tumoricidal properties of saffron (Crocus sativus L.). Exp Biol Med. 2002;227:20-5.
147. Kohno H, Marda M, Honjo S. Prevention of colonic preneoplastic lesions by the beta-cryptoxanthine and hesperidine rich powder prepared from Citrus Unshiu Marc. Juice in male F344 rats. J Toxicol Pathol. 1999;12:209-215.
148. Han SS, Keum YS, Seo HJ, et al. Capsaicin suppresses phorbol ester-induced activation of NF-kappaB/Rel and AP-1 transcription factors in mouse epidermis. Cancer Lett. 2001;164(2):119-26.
149. Yang F, Oz HS, Barve S, et al. The green tea polyphenol (-)-epigallocatechin-3-gallate blocks nuclear factor-kappa B activation by inhibiting I kappa B kinase activity in the intestinal epithelial cell line IEC-6. Mol Pharmacol. 2001;60(3):528-33.
150. Manna SK, Mukhopadhyay A, Aggarwal BB. Resveratrol suppresses TNF-induced activation of nuclear transcription factors NF-kappa B, activator protein-1, and apoptosis: potential role of reactive oxygen intermediates and lipid peroxidation. J Immunol. 2000;164(12):6509-19.
151. Cheng YH, Shen TF, Pang VF, et al. Effects of aflatoxin and carotenoids on growth performance and immune response in mule ducklings. Comp Biochem Physiol Toxicol Pharmacol. 1999;128:19-26.
152. Berkarda B, Koyuncu H, Soybir GT, et al. Inhibitory effect of hesperidin on tumor initiation and promotion in mouse skin. Res Exp Med. 1998;198:93-99.
153. Laughton MJ, Evans PJ, Moroney MA, et al. Inhibition of mammalian 5-lipoxygenase and cyclooxygenase by flavonoids and phenolic dietary additives. Relationship to antioxidant activity and to iron ionreducing ability. Biochem Pharmacol. 1991;42(9):1673-81.
154. Soliman KF, Mazzio EA. In vitro attenuation of nitric oxide production in C6 astrocyte cell culture by various dietary compounds. Proc Soc Exp Biol Med. 1998;218(4):390-7.
155. Kumar A, Dhawan S, Aggarwal BB. Emodin (3-methyl-1,6,8-trihydroxyanthraquinone) inhibits TNF-induced NFkappaB activation, IkappaB degradation, and expression of cell surface adhesion proteins in human vascular endothelial cells. Oncogene. 1998;17(7):913-8.
156. Geng Z, Rong Y, Lau BH. S-Allyl cysteine inhibits activation of nuclear factor kappa B in human T cells. Free Radic Biol Med. 1997;23(2):345-50.
157. Sueoka N, Sueoka E, Okabe S, et al. Anti-cancer effects of morphine through inhibition of tumour necrosis factor-a release and mRNA expression. Carcinogenesis. 1996;17(11):2337-2341.
158. Kune GA, Bannerman S, Field B, et al. Diet, smoking, serum beta-carotene and vitamin A in male nonmelanocytic skin cancer patients and controls. Nutr Cancer. 1992;18(3):237.
159. Gogate SS. Cytotoxicity of neem leaf extract: an antitumor. Natl Med J India. 1991;9:297.
160. Pomponi AS. The bioprocess-technological potential of the sea. J Biotechnol. 1999;70:5-13.
161. Schwartsmann G. Marine organisms and other novel natural sources of new anticancer drugs. Ann Oncol. 2000;11:235-243.
162. Schwartsmann G, Rocha AB, Berlinck R, et al. Marine organisms as a source of new anticancer agents. Lancet Oncol. 2001;2:221-225.
163. Schweitzer J, Handley FG, Edwards J, et al. Summary of the workshop on drug development, biological diversity, and economic growth. J Natl Cancer Inst. 1991;83:1294-1298.
164. Rinehart KL. Antitumor compounds from tunicates. Med Res Rev. 2000;20:1-27.
165. Chun HG, Davies B, Hoth D, et al. Suffness. Didemnin B The first marine compound entering clinical trials as an antineoplastic agent. Invest New Drugs. 1986;4:279-284.
166. Geldof AA, Mastbergen SC, Henrar REC, et al. Cytotoxicity and neurocytoxicity of new marine anticancer agents evaluated using invitro assays. Cancer Chemother Pharmacol. 1999;44:312-318.
167. Demetri G, Garcia-Carbonero R, Harmon D, et al. Ecteinascidin-743 (ET-743) induces objective responses and disease control in patients with advanced non-osseous sarcomas: results from phaseII trials. Ann Oncol. 2000;11(Suppl 4):126.
168. Erba E, Bergamaschi D, Bassano L, et al. Ecteinascidin-743 (ET-743), a natural marine compound, with a unique mechanism of action. Eur J Cancer. 2001;37:97-105.
169. Damia G, Silvestri S, Carrassa L, et al. Unique pattern of ET-743 activity in different cellular systems with defined deficiencies in DNA-repair pathways. Int J Cancer. 2001;92:583-588.
170. Poncet J. The dolastatins, a family of promising antineoplastic agents. Curr Pharm Des. 1999;5:139-162.
171. Bai R, Pettit GR, Hamel E. Dolastatin10, a powerful cytostatic peptide derived from a marine animal. Inhibition of tubulin polymerization mediated through the vinca alkaloid binding domain. Biochem Pharmacol. 1990;39:1941-1949.
172. Pathak S, Multani AS, Ozen M, et al. Dolastatin10 induces polyploidy, telomeric associations and apoptosis in a murine melanoma cell line. Oncol Res. 1998;5:373-376.
173. Pettit GR. The bryostatins. Fortschr Chem Org Naturst. 1991;57:153-195.
174. Pagliaro L, Daliani D, Amato R, et al. Phase II trial of bryostatin-1 for patients with metastatic renal cell carcinoma. Cancer. 2000;89:615-618.
175. Varterasian ML, Mohammad RM, Shurafa MS, et al. PhaseII trial of bryostatin1 in patients with relapsed low-grade non-Hodgkin's lymphoma and chronic lymphocytic leukemia. Clin Cancer Res. 2000;6:825-828.
176. Zonder JA, Shields AF, Zalupski M, et al. A phase II trial of bryostatin 1 in the treatment of metastatic colorectal cancer. Clin Cancer Res. 2001;7:38-42.
177. Ahmad I, Al-Katib AM, Beck FW, et al. Sequential treatment of a resistant chronic lymphocytic leukemia patient with bryostatin1 followed by 2-chlorodeoxyadenoside: case report. Clin Cancer Res. 2000;6:1328-1332.
178. Mayer A and Gustafson KR. Marine pharmacology in 2002-2004: Anti-tumour and cytotoxic compounds. Eur J Cancer. 2006;42:2241-2270.
179. Mayer A and Gustafson K R. Marine pharmacology in 2005-2006: Anti-tumour and cytotoxic compounds. Eur J Cancer. 2008;44: 2257-2287.
180. Binaschi M, Farinosi R, Borgnetto ME, et al. In vivo site specificity and human isoenzyme selectivity of two topoisomerase II poisoning anthracyclines. Cancer Res. 2000;60:3770-3776.
181. Patrick Y. Major microbial diversity initiative recommended. Am Soc Microbiol News. 1997;63:417-421.
182. Alberts MW, Williams RT, Brown EJ, et al. KBP-Rapamycin inhibits a cyclin-dependent kinase activity and a cyclin D1-Cdk association in early Gl of an osteosarcoma cell line. J Biol Chem. 1993;268:22825-22829.
183. Schulte TW, Neckers LM. The benzoquinone ansamycin 17-allylamino-17 demethoxygeldanamycin binds to HSP90 and shares important biologic activities with geldanamycin. Cancer Chemother Harmacol. 1998;42:273-279.
184. Cadenas ME, Sandfrison A, Cutler NS, et al. Signal transduction cascades as targets for therapeutic intervention by natural products. Trends Biotechnol. 1998;16:427-433.
185. Adjei AA. Signal transduction pathway targets for anticancer drug discovery. Curr Pharmaceut Design. 2000;6:361-378.